Shared on05 Sep 25
Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90. What's in the News Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.
Shared on23 Apr 25Fair value Decreased 0.50%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 3.01%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 8.09%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 17%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 20%
AnalystConsensusTarget has decreased revenue growth from 28.5% to 19.8% and decreased profit margin from 35.8% to 32.2%.
Shared on19 Mar 25Fair value Increased 1.38%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on13 Mar 25Fair value Increased 28%
AnalystConsensusTarget has increased revenue growth from 15.3% to 28.5%, increased profit margin from 29.8% to 35.8% and increased shares outstanding growth rate from 0.0% to 0.1%.